Pre-clinical experimentation and clinical research
Pre-clinical experimentation and clinical research
Contact
Arronax Nantes > Pre-clinical experimentation and clinical research > Our publications > Article > 2019

Preclinical experimentation and clinical research

  • What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between 89Zr- and 64Cu-Labeled Anti-CD138 in a Preclinical Syngeneic Model, Bailly C, Gouard S, Guérard F, Chalopin B, Carlier T, Faivre-Chauvet A, et al., IJMS. 24 mai 2019;20(10):2564.

  • Preliminary results of a 68 Ga‐PSMA PET/CT prospective study in prostate cancer patients with occult recurrence: Diagnostic performance and impact on therapeutic decision‐making, Rousseau C, Le Thiec M, Ferrer L, Rusu D, Rauscher A, Maucherat B, et al. , Prostate. 17 août 2019;pros.23869

  • Potential for Nuclear Medicine Therapy for Glioblastoma Treatment, Bailly C, Vidal A, Bonnemaire C, Kraeber-Bodéré F, Chérel M, Pallardy A, et al., Front Pharmacol. 10 juill 2019;10:772.

  • Exploring Tumor Heterogeneity Using PET Imaging: The Big Picture, Bailly C, Bodet-Milin C, Bourgeois M, Gouard S, Ansquer C, Barbaud M, et al., Cancers. 31 août 2019;11(9):1282.

  • Clinical Results in Medullary Thyroid Carcinoma Suggest High Potential of Pretargeted Immuno-PET for Tumor Imaging and Theranostic Approaches, Bodet-Milin C, Bailly C, Touchefeu Y, Frampas E, Bourgeois M, Rauscher A, et al., Front Med. 4 juin 2019;6:124.